Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Iodine-125 methylene blue** is an investigational dual-modality radiolabeled dye used for intraoperative sentinel lymph node mapping in women with breast cancer. Following subcutaneous periareolar injection, methylene blue travels through lymphatic channels and visually stains draining sentinel lymph nodes, while its iodine-125 label provides a gamma-detectable signal for surgical localization. An extended Phase II study reported successful sentinel-node identification in 94% of enrolled patients and supported its use as an intraoperatively prepared alternative to technetium-99m sulfur colloid plus blue dye. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/23521938/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iodine-125 methylene blue.